Socializing a Science-Based Digital Therapeutic for Substance Use Disorders
Condition(s) studied
Investigational drug(s) / intervention(s)
Laddr® plus Behavioral- Group and individual counseling: Smartphone application utilizing the Community Reinforcement Approach (CRA) to facilitate social support in substance use treatment. Outpatient treatment will include a range of services, including group counseling, individual counseling, medication treatment, and other recovery support services.
Behavioral- Group and individual counseling: The active control condition consists of standard outpatient treatment for substance use disorders. Outpatient treatment will include a range of services, including group counseling, individual counseling, medication treatment, and other recovery support services.
Study summary
The purpose of this study is to evaluate the effectiveness of an intervention delivered on a smartphone. This study examines whether this intervention might improve treatment outcomes for people with substance use disorders. The intervention, called Laddr®, is a smartphone application ("app") that provides information and skills that can help people stop using substances. The social version of Laddr® being tested in this study has new features that allow people in treatment for substance use disorders to include a support person in their treatment journey, including a friend, family member, or other acquaintance. This research study will compare the effectiveness of Laddr® in combination with standard outpatient substance use treatment to standard treatment only for substance use disorders.
Eligibility
Primary outcome measure(s)
- Retention in treatment Retention in treatment Retention in treatment Retention in treatment Retention in treatment — 16 weeks
Time between randomization and dropout from standard outpatient treatment
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Farnum Center | Manchester | New Hampshire |
More Square2 Systems, Inc. trials in the USA
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05648786 on ClinicalTrials.gov ↗ ← All trials in the USA